Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 439Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 245Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

ON 01910 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Anemia, Refractory × Clear all
NCT00854945 2017-06-26

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Traws Pharma, Inc.

Phase 1/2 Completed
36 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡